Progressive Supranuclear Palsy (PSP) Clinical Trials

8 recruitingLast updated: June 18, 2026

There are 8 actively recruiting progressive supranuclear palsy (psp) clinical trials across 5 countries. Studies span Early Phase 1, Not Applicable. Top locations include Philadelphia, Pennsylvania, United States, Boston, Massachusetts, United States, Baltimore, Maryland, United States. Updated daily from ClinicalTrials.gov.


Progressive Supranuclear Palsy (PSP) Trials at a Glance

8 actively recruiting trials for progressive supranuclear palsy (psp) are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Early Phase 1 with 1 trial, with the heaviest enrollment activity in Philadelphia, Boston, and Baltimore. Lead sponsors running progressive supranuclear palsy (psp) studies include Beijing Tiantan Hospital, Invicro, and Centre Hospitalier Universitaire de Liege.

Browse progressive supranuclear palsy (psp) trials by phase

Treatments under study

About Progressive Supranuclear Palsy (PSP) Clinical Trials

Looking for clinical trials for Progressive Supranuclear Palsy (PSP)? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Progressive Supranuclear Palsy (PSP) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Progressive Supranuclear Palsy (PSP) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Synaptic Loss in Multiple System Atrophy

Multiple System AtrophyProgressive Supranuclear Palsy (PSP)
University of Exeter36 enrolled1 locationNCT05121012
Recruiting

Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers

Healthy ControlMultiple System AtrophyProgressive Supranuclear Palsy (PSP)+1 more
Beijing Tiantan Hospital720 enrolled1 locationNCT07392411
Recruiting

UPenn Observational Research Repository on Neurodegenerative Disease

Corticobasal Syndrome(CBS)Progressive Supranuclear Palsy (PSP)Primary Progressive Aphasia(PPA)+6 more
University of Pennsylvania1,000 enrolled1 locationNCT04715399
Recruiting

The CurePSP Genetics Program

Multiple System Atrophy, Parkinsonian TypeMultiple System Atrophy, Cerebellar TypeMultiple System Atrophy+15 more
Massachusetts General Hospital1,000 enrolled1 locationNCT06647641
Recruiting
Early Phase 1

First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain

Healthy ParticipantsProgressive Supranuclear Palsy (PSP)
Invicro24 enrolled1 locationNCT07348276
Recruiting
Not Applicable

Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology

Myasthenia GravisHuntington DiseaseNeuromuscular Diseases+9 more
Centre Hospitalier Universitaire de Liege300 enrolled1 locationNCT07136844
Recruiting

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Amyotrophic Lateral SclerosisCorticobasal Degeneration (CBD)Progressive Supranuclear Palsy (PSP)+11 more
Mayo Clinic2,100 enrolled27 locationsNCT04363684
Recruiting

AI-Enhanced Optimization of Acute Levodopa Challenge Test

Corticobasal Degeneration (CBD)Progressive Supranuclear Palsy (PSP)Parkinson Disease (PD)+4 more
Beijing Tiantan Hospital2,000 enrolled1 locationNCT06949865